• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Lin,DUAN Xiuran,LIU Wei.Research progress on the differentiation and risk attribution of traditional Chinese medicine induced hepatotoxicity and related liver injury[J].Journal Of Pharmaceutical Research,2026,45(9):1058-1064[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 229times   Download 216次 QR Code for this article
Scan with your phone!
中药致肝毒性及相关肝损伤辨析与风险归因研究进展
张琳1,段修冉1,刘伟2
Font:Larger+|Default|Smaller-
(1.山东第一医科大学第二附属医院药学部,山东 泰安 271000;2.齐鲁工业大学<山东省科学院>,山东省分析测试中心,山东 济南 250014)
摘要:
中药是我国传统医药体系的核心组成部分,是临床防病治病的重要物质基础。随着中医药临床应用的广泛推广,中药用药安全已成为行业与公众关注的核心议题,其中中药相关药物性肝损伤(DILI)的发生机制与风险防控是研究热点。目前学界存在固有肝毒性与不合理用药致肝损伤概念混淆、肝毒性药材统计口径不统一等问题,易引发公众对中药安全性的误解。因此,本文基于中药系统毒理学数据库权威数据、《中国药典》2025年版毒性药材分级标准,结合近年核心文献报道,明确界定中药固有肝毒性与用药相关肝损伤的核心差异,系统梳理固有肝毒性中药的分类、核心毒性成分与肝损伤作用机制,建立非固有毒性药材肝损伤的归因甄别标准,甄别其核心风险因素。
关键词:  固有肝毒性中药  药物性肝损伤  毒性成分  风险因素  合理用药  风险规避
DOI:10.13506/j.cnki.jpr.2026.09.015
基金项目:
Received Date:May 09, 2026   Revision Date:July 28, 2026   Publication Date:September 30, 2026
Research progress on the differentiation and risk attribution of traditional Chinese medicine induced hepatotoxicity and related liver injury
ZHANG Lin1,DUAN Xiuran1,LIU Wei2
(1.Department of Pharmacy,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China;2.Qilu University of Pharmaceutical Technology,Shandong Analytical and testing Center,Jinan 250014,China)
Abstract:
Traditional Chinese medicine (TCM) is a core component of China's traditional medical system and serves as a crucial material foundation for disease prevention and treatment in clinical practice. With the widespread application of TCM in clinical settings, drug safety has become a central concern for both the industry and the public, particularly regarding the mechanisms and risk prevention of drug-induced liver injury (DILI) associated with TCM. Currently, academic circles face challenges such as confusion between intrinsic hepatic toxicity and liver damage caused by inappropriate medication use, as well as inconsistent criteria for classifying hepatotoxic herbs—issues that can lead to public misunderstanding about TCM safety. Therefore, based on authoritative data from the System Toxicology Database of Traditional Chinese Medicine and the 2025 edition of the Chinese Pharmacopoeia's classification standards for toxic herbs, and incorporating recent key literature, this article clearly defines the fundamental differences between intrinsic hepatic toxicity and drug-related liver injury in TCM. It systematically organizes the classification of intrinsically hepatotoxic herbs, their key toxic components, and underlying mechanisms of liver injury, establishes diagnostic criteria for attributing liver injury caused by non-intrinsically toxic herbs, and identifies their core risk factors.
Key words:  Inherent hepatotoxic traditional Chinese medicine  Drug-induced liver injury  Toxic components  Risk factors  Rational medication  Risk avoidance
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.